News
Company News: Allero Therapeutics´ Immunotherapy Approach in Food-Induced Immune Disorders Validated by Two Peer-Reviewed Publications
– Promising data in celiac disease patients
– Specific OroMucosal ImmunoTherapy concept supported by animal data
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further detailing and validating its approach to combat food-induced immune disorders with its SOMIT (Specific OroMucosal ImmunoTherapy) platform technology.
Company News: Neonatal Diagnostics Company InfanDx Closesx Interim Financing Round
— Funding allows further advancement of lead product and achievement of key near-term milestones
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the closing of an interim financing round involving both existing and new investors. The proceeds from this funding round are expected to provide the financial runway to achieve certain value-creating near-term milestones in clinical biomarker research for the Company’s lead product, the HypoxE test®. Further details of the financing round were not disclosed.
Company News: BellaSeno and Fraunhofer Institute for Production Technology IPT Receive EUR 1.4 Million BMBF Grant
— Funding dedicated to the development of commercial-scale, fully automated additive manufacturing of resorbable medical implants
— First-ever industrial-scale, additive manufacturing platform of medical implants
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, and the Fraunhofer Institute for Production Technology IPT today announced that both parties have received a grant totaling EUR 1.4 million from Germany´s Federal Ministry of Education and Research (BMBF) under the funding program KMU-innovativ.
Company News: SEQ-IT Reports Breakthrough in the Rapid Variant Diagnosis of SARS-CoV-2
SEQ-IT, a leading molecular services provider, today announced they completed a novel mass spectrometry based rapid test for the detection of 20 of the most relevant SARS-CoV-2 mutations including the UK (B.1.1.7), South African and Brazilian variants. The test panel was developed using Agena Bioscience’s MassARRAY® System, a well-established tool used by clinical laboratories worldwide to deliver affordable, highly accurate genomic testing.